奥马珠单抗治疗儿童重度过敏性哮喘的快速卫生技术评估

A rapid health technology assessment of omalizumab in the treatment of children with severe allergic asthma

为评估奥马珠单抗治疗儿童重度过敏性哮喘的有效性、安全性和经济性,检索国内外相关文献数据库和卫生技术评估组织官网,共纳入9篇文献,应用快速卫生技术评估方法进行评估。结果显示,对于儿童重度过敏性哮喘,奥马珠单抗治疗可显著降低患者哮喘急性重度发作的风险,缓解临床症状,减少控制用药剂量,同时不良反应发生率低,安全性好。但奥马珠单抗目前售价昂贵,与安慰剂或哮喘标准治疗相比不具有成本效果优势。

To quickly evaluate the efficacy,safety and economy of omalizumab in the treatment of children with severe allergic asthma.A total of 9 reports were included by searching domestic and foreign related literature databases and the official website of the health technology assessment organization,which were evaluated by a rapid health technology assessment method.The results showed that omalizumab could significantly reduce the risk of acute severe asthma and the dosage of control medication,and alleviate clinical symptoms for children with severe allergic asthma.At the same time,the incidence of adverse reactions was low and the safety was good.Economic studies at home and abroad showed that omalizumab was not a costeffective option compared with standard therapy or placebo in children with severe allergic asthma because of its high price.